Drugs / Lacidipine

Trials 9 · a red edge is where a trial was stopped

199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT02203500 Oct 1998 → Jan 1999 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02218684 Sep → Nov 1998 Boehringer Ingelheim Completed No outcome recorded
Phase 21 trial
Phase 2 NCT02232607 Apr 1998 → Jun 1999 Boehringer Ingelheim Completed No outcome recorded
Phase 31 trial
Phase 3 NCT02177331 Jun 1995 → Jan 1998 hypertensive disorder Boehringer Ingelheim Completed No outcome recorded
Phase 45 trials
Phase 4 NCT00533858 Sep 2007 → Sep 2008 hypertensive disorder Seoul National University Hospital Unknown No outcome recorded
Phase 4 NCT00460915 Jan 2007 → Jul 2009 hypertensive disorder Korea University Guro Hospital Completed No outcome recorded
Phase 4 NCT00338338 Nov 2005 → Sep 2007 essential hypertension GlaxoSmithKline Completed No outcome recorded
Phase 4 NCT00328965 Nov 2004 → May 2006 essential hypertension, type 2 diabetes mellitus GlaxoSmithKline Completed No outcome recorded
Phase 4 NCT02235402 Dec 1997 → Mar 2000 hypertensive disorder Boehringer Ingelheim Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02264158 Comparator Sep 2001 → Mar 2002 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02209649 Comparator Oct → Dec 1999 Boehringer Ingelheim Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as Lacidipine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02177331
10

NCT02218684

NCT02232607

NCT02235402

NCT02209649

NCT00338338

NCT00533858

NCT00460915

NCT02203500

NCT02264158

NCT00328965

Known as GR 43659X ChEMBL registry synonym — accepted as the source's own label CHEMBL460291
Known as Lacidipino ChEMBL registry synonym — accepted as the source's own label CHEMBL460291
Known as Molap ChEMBL registry synonym — accepted as the source's own label CHEMBL460291
Known as Motens ChEMBL registry synonym — accepted as the source's own label CHEMBL460291
Modality Small molecule CHEMBL460291
Route Oral “Lacidipine 4 or 6 mg (oral)” NCT00338338